Health Economics›Head and neck cancer›Locally advanced disease induction

Locally advanced disease induction

Head and neck cancer · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cisplatin and Fluorouracil (CF) Variant #29	—	R 1 900	21d	11.3 mo	9.0 mo	17	R 32 301 PFS proxy	8
PCF N/A - secondary systemic drug	—	R 604	21d	—	—	—	—	—
DCF N/A - secondary systemic drug	—	R 228	21d	12.8 mo	36.8 mo	19	R 4 323 PFS proxy	7
No induction Partial	—	—	—	—	31.7 mo	—	—	2

4 of 4 regimens shown